Compounds / Immune / Thymosin Alpha-1

Thymosin Alpha-1

Thymosin Alpha-1 (Tα1 — 28-AA Thymic Peptide)
ImmuneWell ResearchedFDA: Not FDA-approved (approved as Zadaxin...

Overview

Approved equivalent (Zadaxin) in 35+ countries. Hepatitis B/C, immunocompromised states, COVID-19 observational data. Robust human clinical data.

Mechanism of Action

Thymic-derived peptide. Augments T-cell function, NK cell activity, dendritic cell maturation. Upregulates MHC class I antigen expression. Th1 cytokine profile promotion. TLR9 agonist activity.

Pharmacokinetics

Half-life
2 hrs
Peak (Tmax)
2 hrs
Cleared
~10 hrs

Molecular Profile

Molecular weight
3,108 Da
CAS number
62304-98-7
Type
Acetylated polypeptide
Length
28 amino acids
Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH

Key Research Findings

T-cell/NK augmentation; approved in 35+ countries (Zadaxin); hepatitis B/C treatment data; COVID-19 benefit.

Published Research

Ann NY Acad Sci
Romani L et al. Thymosin α1: endogenous regulator of inflammation, immunity and tolerance
View source

Related Immune Compounds

LL-37ThymalinThymulinVIP (Vasoactive Intestinal Peptide)
Clinical Guidance

Research data is not a treatment plan. If you are considering Thymosin Alpha-1, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Thymosin Alpha-1? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals